Acta Pharmaceutica Sinica B

Scope & Guideline

Unlocking New Horizons in Pharmacology and Toxicology

Introduction

Explore the comprehensive scope of Acta Pharmaceutica Sinica B through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Acta Pharmaceutica Sinica B in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2211-3835
PublisherINST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
Support Open AccessYes
CountryChina
TypeJournal
Converge2012, from 2014 to 2024
AbbreviationACTA PHARM SIN B / Acta Pharm. Sin. B
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressC/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING 100050, PEOPLES R CHINA

Aims and Scopes

Acta Pharmaceutica Sinica B is a leading journal that focuses on the intersection of pharmaceutical sciences and biotechnology, emphasizing innovative drug discovery, development, and delivery methods. The journal aims to publish high-quality research that advances the understanding of medicinal chemistry, pharmacology, and therapeutic applications.
  1. Drug Discovery and Development:
    The journal covers innovative approaches in drug discovery, including small molecules, biologics, and traditional medicines, emphasizing their mechanisms of action and therapeutic potential.
  2. Nanomedicine and Drug Delivery Systems:
    Significant focus on nanotechnology for drug delivery, exploring the design, synthesis, and application of nanocarriers to enhance therapeutic efficacy and reduce side effects.
  3. Pharmacology and Toxicology:
    Research on the pharmacokinetics, pharmacodynamics, and toxicological evaluations of new drugs, providing insights into their safety and efficacy profiles.
  4. Biotechnology and Molecular Biology:
    Studies that leverage biotechnological advancements, including CRISPR and gene editing, for therapeutic purposes, particularly in cancer and genetic diseases.
  5. Phytochemistry and Natural Products:
    Exploration of bioactive compounds from natural sources, including their pharmacological effects, mechanisms of action, and potential for drug development.
  6. Clinical Translational Research:
    Research that bridges laboratory findings with clinical applications, focusing on the development of new therapeutic strategies and improving patient outcomes.
Acta Pharmaceutica Sinica B has seen a surge in research themes that reflect the latest trends and advancements in pharmaceutical sciences. These emerging scopes indicate a shift towards innovative methodologies and therapeutic strategies.
  1. Immunotherapy and Checkpoint Inhibition:
    Research focusing on immunotherapy, especially combination therapies that enhance immune response against tumors, has gained significant traction, indicating a paradigm shift in cancer treatment.
  2. Nanomedicine Innovations:
    There is a growing trend in the development of novel nanomedicine platforms for targeted drug delivery, including stimuli-responsive systems that enhance therapeutic efficacy and minimize side effects.
  3. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene-editing technologies in drug development and disease treatment has emerged as a prominent theme, highlighting the potential for genetic therapies.
  4. Microbiome Research:
    Studies exploring the role of the gut microbiome in drug metabolism and therapeutic responses are gaining importance, reflecting a broader interest in personalized medicine.
  5. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is becoming increasingly prevalent, showcasing efforts to improve efficiency and accuracy in identifying potential drug candidates.
  6. Sustainable and Green Chemistry:
    Research emphasizing sustainable practices in drug development, including the use of renewable resources and eco-friendly processes, is on the rise, aligning with global sustainability goals.

Declining or Waning

While Acta Pharmaceutica Sinica B continues to thrive in numerous research areas, certain themes have shown signs of declining interest or publication frequency. These waning scopes reflect shifts in research focus and the evolving landscape of pharmaceutical sciences.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused on traditional drug formulations, as research shifts toward novel delivery systems and advanced drug formulations.
  2. Conventional Chemotherapy Approaches:
    The focus on conventional chemotherapy methods is waning in favor of targeted therapies and immunotherapies, indicating a shift toward more personalized medicine.
  3. Basic Pharmacognosy Studies:
    Research specifically centered on pharmacognosy without the application of modern techniques or translational potential has decreased, as the field moves towards integrating pharmacognosy with molecular biology.
  4. Single-Drug Therapy Studies:
    The decline in publications focusing solely on single-drug therapies suggests a growing interest in combination therapies and multi-target approaches to enhance treatment efficacy.

Similar Journals

JOURNAL OF PHARMACY AND PHARMACOLOGY

Elevating pharmaceutical sciences to new heights.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

Iranian Journal of Pharmaceutical Research

Exploring innovative solutions in pharmaceutical sciences.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Advancing Pharmaceutical Innovation and Excellence
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Advances in Pharmacology and Pharmacy

Pioneering Discoveries in Drug Development
Publisher: HORIZON RESEARCH PUBLISHINGISSN: 2332-0036Frequency: 3 issues/year

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.

Ars Pharmaceutica

Advancing pharmaceutical knowledge through open dialogue.
Publisher: UNIV GRANADA, EDITORIALISSN: 0004-2927Frequency: 4 issues/year

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

DARU-Journal of Pharmaceutical Sciences

Empowering researchers to shape the future of medicine.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Journal of Reports in Pharmaceutical Sciences

Unveiling the Future of Biopharmaceutical Technologies.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

International Journal of Pharmaceutical Investigation

Empowering Researchers with Insightful Pharmaceutical Knowledge
Publisher: INPHARM ASSOC, PHCOG NETISSN: 2230-973XFrequency: 4 issues/year

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

International Journal of Pharmacology

Fostering Global Dialogue in Pharmacology and Toxicology
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

ADVANCED DRUG DELIVERY REVIEWS

Exploring Innovations in Drug Delivery.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.